Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Chemorefractory Germ Cell Carcinoma
NCT00772694Phase 2Unknown
- Sponsor
- Wygrajmy Zdrowie
- Start
- Sep 2008
- Primary completion
- Dec 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in testicular cancer, sponsored by Wygrajmy Zdrowie. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
sorafenib
03
Conditions
testicular cancer
Beyond the preview
Go deeper on NCT00772694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772694.